GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eusol Biotech Co Ltd (ROCO:6652) » Definitions » EV-to-EBITDA

Eusol Biotech Co (ROCO:6652) EV-to-EBITDA : -18.75 (As of Jun. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eusol Biotech Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eusol Biotech Co's enterprise value is NT$842.99 Mil. Eusol Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-44.95 Mil. Therefore, Eusol Biotech Co's EV-to-EBITDA for today is -18.75.

The historical rank and industry rank for Eusol Biotech Co's EV-to-EBITDA or its related term are showing as below:

ROCO:6652' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.58   Med: -8.27   Max: -2.86
Current: -18.75

During the past 9 years, the highest EV-to-EBITDA of Eusol Biotech Co was -2.86. The lowest was -20.58. And the median was -8.27.

ROCO:6652's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.15 vs ROCO:6652: -18.75

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Eusol Biotech Co's stock price is NT$8.89. Eusol Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-0.380. Therefore, Eusol Biotech Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Eusol Biotech Co EV-to-EBITDA Historical Data

The historical data trend for Eusol Biotech Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eusol Biotech Co EV-to-EBITDA Chart

Eusol Biotech Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -29.44 -36.75 -18.44 66.28 -21.92

Eusol Biotech Co Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.44 - 66.28 - -21.92

Competitive Comparison of Eusol Biotech Co's EV-to-EBITDA

For the Biotechnology subindustry, Eusol Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eusol Biotech Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eusol Biotech Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Eusol Biotech Co's EV-to-EBITDA falls into.



Eusol Biotech Co EV-to-EBITDA Calculation

Eusol Biotech Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=842.992/-44.951
=-18.75

Eusol Biotech Co's current Enterprise Value is NT$842.99 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eusol Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-44.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eusol Biotech Co  (ROCO:6652) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Eusol Biotech Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.89/-0.380
=At Loss

Eusol Biotech Co's share price for today is NT$8.89.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eusol Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-0.380.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Eusol Biotech Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Eusol Biotech Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Eusol Biotech Co (ROCO:6652) Business Description

Traded in Other Exchanges
N/A
Address
Minsheng E. Road, 6th Floor, No.135, Sec.3, Songshan District, Taipei, TWN, 10546
Eusol Biotech Co Ltd is a Taiwan based company that invests in developing new drugs to fulfill unmet medical needs. Its pipeline products include ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with the sedative effect.

Eusol Biotech Co (ROCO:6652) Headlines

No Headlines